Onconova Therapeutics announces closing of $10 million underwritten public offering
Onconova Therapeutics announced the closing of its previously announced underwritten public offering of 9,947,500 shares of its common stock and warrants to purchase an aggregate of 994,750 shares of Onconova’s Series A convertible preferred stock. February 12, 2018